165 related articles for article (PubMed ID: 22471667)
1. Targeting the human kinome for cancer therapy.
Daly RJ
Crit Rev Oncog; 2012; 17(1):vi-vii. PubMed ID: 22471667
[No Abstract] [Full Text] [Related]
2. Overcoming Resistance to Targeted Therapies in Cancer.
Redmond KL; Papafili A; Lawler M; Van Schaeybroeck S
Semin Oncol; 2015 Dec; 42(6):896-908. PubMed ID: 26615134
[TBL] [Abstract][Full Text] [Related]
3. Targeting the ERBB family in cancer: couples therapy.
Tebbutt N; Pedersen MW; Johns TG
Nat Rev Cancer; 2013 Sep; 13(9):663-73. PubMed ID: 23949426
[TBL] [Abstract][Full Text] [Related]
4. The pharmacogenomics of drug resistance to protein kinase inhibitors.
Gillis NK; McLeod HL
Drug Resist Updat; 2016 Sep; 28():28-42. PubMed ID: 27620953
[TBL] [Abstract][Full Text] [Related]
5. Companion biomarkers: paving the pathway to personalized treatment for cancer.
Duffy MJ; Crown J
Clin Chem; 2013 Oct; 59(10):1447-56. PubMed ID: 23656699
[TBL] [Abstract][Full Text] [Related]
6. BRAF Inhibitors for the Treatment of Papulopustular Eruptions from MAPK Pathway Inhibitors.
Wang CJ; Brownell I
Am J Clin Dermatol; 2020 Dec; 21(6):759-764. PubMed ID: 32720072
[TBL] [Abstract][Full Text] [Related]
7. Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside.
Röring M; Brummer T
Crit Rev Oncog; 2012; 17(1):97-121. PubMed ID: 22471666
[TBL] [Abstract][Full Text] [Related]
8. Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit.
Kato S; Subbiah V; Kurzrock R
J Natl Compr Canc Netw; 2017 Jul; 15(7):863-866. PubMed ID: 28687573
[No Abstract] [Full Text] [Related]
9. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
Hainsworth JD; Meric-Bernstam F; Swanton C; Hurwitz H; Spigel DR; Sweeney C; Burris H; Bose R; Yoo B; Stein A; Beattie M; Kurzrock R
J Clin Oncol; 2018 Feb; 36(6):536-542. PubMed ID: 29320312
[TBL] [Abstract][Full Text] [Related]
10. The influence of subclonal resistance mutations on targeted cancer therapy.
Schmitt MW; Loeb LA; Salk JJ
Nat Rev Clin Oncol; 2016 Jun; 13(6):335-47. PubMed ID: 26483300
[TBL] [Abstract][Full Text] [Related]
11. A new standard of care for metastatic melanoma?
Sharma SP
Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559
[No Abstract] [Full Text] [Related]
12. Systemic treatment for metastatic colorectal cancer in the era of precision medicine.
Sandhu J; Lavingia V; Fakih M
J Surg Oncol; 2019 Apr; 119(5):564-582. PubMed ID: 30802315
[TBL] [Abstract][Full Text] [Related]
13. The importance of persistence in cancer drug development.
Mullard A
Nat Rev Drug Discov; 2021 Dec; 20(12):890-891. PubMed ID: 34764465
[No Abstract] [Full Text] [Related]
14. Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors.
Ruiz-Camps I; Aguilar-Company J
Infect Dis Clin North Am; 2020 Jun; 34(2):257-270. PubMed ID: 32334988
[TBL] [Abstract][Full Text] [Related]
15. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
Brechbiel J; Miller-Moslin K; Adjei AA
Cancer Treat Rev; 2014 Jul; 40(6):750-9. PubMed ID: 24613036
[TBL] [Abstract][Full Text] [Related]
16. Combination therapies for treating metastatic melanoma.
Tawbi H
Clin Adv Hematol Oncol; 2015 Apr; 13(4):211-4. PubMed ID: 26352577
[No Abstract] [Full Text] [Related]
17. Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma.
Long G
Clin Adv Hematol Oncol; 2018 Jan; 16(1):25-27. PubMed ID: 29741501
[No Abstract] [Full Text] [Related]
18. Strides in melanoma announced: maximizing value comes next.
Tuma RS
J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727
[No Abstract] [Full Text] [Related]
19. Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
Roy M; Sarkar R; Mukherjee A; Mukherjee S
Chem Biol Interact; 2015 Dec; 242():195-201. PubMed ID: 26456889
[TBL] [Abstract][Full Text] [Related]
20. Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms.
Ozkaya N; Dogan A; Abdel-Wahab O
Hematol Oncol Clin North Am; 2017 Aug; 31(4):705-719. PubMed ID: 28673397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
